

Supplementary Table 3. Baseline characteristics by sex

Variable	Women (n = 12)	Men (n = 38)	p value
Clinical			
Age, yr	70.0 (60.5–77.0)	66.5 (57.8–73.0)	0.333
Body mass index, kg/m ²	23.0 (21.7–24.3)	23.0 (20.9–24.9)	0.884
Body surface area, m ²	1.5 (1.4–1.6)	1.8 (1.7–1.9)	< 0.001
Severe diabetes mellitus	3 (25.0)	12 (31.5)	1.000
Chronic renal disease	7 (58.3)	15 (39.4)	0.492
Prior cardiac surgery	2 (16.6)	14 (36.8)	0.292
Ischemic heart disease	6 (50.0)	22 (57.8)	0.631
INTERMACS profile			
Critical cardiogenic shock	0	2 (5.2)	1.000
Progressive decline	4 (33.3)	11 (28.9)	1.000
Stable but inotrope-dependent	8 (66.6)	22 (57.8)	0.740
Resting symptoms	0	3 (7.8)	1.000
LV ejection fraction	20.9 (14.7–27.2)	22.5 (19.2–26.0)	0.401
> 50%	0	0	-
40%–49%	0	0	-
30%–39%	2 (16.6)	5 (13.1)	1.000
20%–29%	7 (58.3)	18 (47.3)	0.508
< 20%	3 (25.0)	15 (39.4)	0.497
LV end-diastolic diameter, cm	6.6 (5.8–7.7)	6.9 (6.2–7.5)	0.417
NYHA class			
III	3 (25.0)	4 (10.5)	0.337
IV	9 (75.0)	34 (89.4)	0.337
Laboratory			
Hemoglobin, g/dL	10.9 (9.6–12.4)	10.3 (9.2–12.8)	0.682
White blood cell count, × 1,000/μL	7.6 (6.7–8.5)	7.3 (5.5–9.1)	0.606
Platelets, × 1,000/μL	197.5 (93.3–235.8)	145.0 (91.5–200.3)	0.499
Blood urea nitrogen, mg/dL	17.3 (14.3–29.1)	24.1 (16.8–47.0)	0.180
Creatinine, mg/dL	1.1 (0.9–1.8)	1.4 (0.9–1.8)	0.683
Albumin, g/dL	3.6 (3.0–4.0)	3.5 (3.0–3.9)	0.977
ALT, μ/L	21.0 (15.8–27.5)	29.5 (16.8–77.3)	0.125
AST, μ/L	27.0 (20.3–29.8)	34.0 (21.8–74.5)	0.270
Total bilirubin, mg/dL	1.5 (0.8–2.8)	1.5 (0.9–2.5)	0.820
INR	1.2 (1.1–1.5)	1.2 (1.1–1.4)	0.514
Sodium, mmol/L	130.5 (128.0–136.3)	135.0 (131.8–139.0)	0.040
hsCRP, mg/L	20.0 (2.8–42.1)	11.7 (4.5–34.2)	0.716
NT-proBNP, pg/mL	17,244 (11,755–35,000)	7,563 (4,255–12,958)	0.002
Preoperative			
ECMO bridged	1 (8.3)	10 (26.3)	0.257
Dialysis	3 (25.0)	12 (31.5)	1.000
IABP	0	1 (2.6)	1.000
Ventilator	2 (16.6)	13 (34.2)	0.304

Supplementary Table 3. Continued

Variable	Women (n = 12)	Men (n = 38)	p value
Hemodynamic			
Mean RA pressure, mmHg	9.0 (4.0–15.0)	12.5 (8.0–16.5)	0.151
Mean PA pressure, mmHg	38.0 (29.0–43.0)	38.5 (31.8–43.3)	0.384
Mean PWP, mmHg	21.0 (16.0–29.0)	27.0 (22.5–31.5)	0.163
Cardiac output, L/min	2.7 (2.5–3.4)	3.5 (2.8–4.2)	0.010
Medications			
ARB or ARNI	9 (75.0)	23 (60.5)	0.497
ACE inhibitor	7 (58.3)	9 (23.6)	0.036
Amiodarone	4 (33.3)	25 (65.7)	0.047
Beta blocker	7 (58.3)	20 (52.6)	0.730
Aldosterone antagonist	12 (100)	36 (94.7)	1.000
Ivabradine	4 (33.3)	8 (21.0)	0.448
Loop diuretics	12 (100)	37 (97.3)	1.000
Phosphodiesterase inhibitors	7 (58.3)	16 (42.1)	0.325
ICD	3 (25.0)	10 (26.3)	1.000
CRT	4 (33.3)	5 (13.1)	0.191
Implant strategy			
BTT/BTC	6 (50.0)	24 (63.2)	0.506
DT	6 (50)	14 (36.8)	0.506
Device type			
Heartmate II™	0	17 (44.7)	0.004
HVAD™	12 (100)	21 (55.2)	0.004

Values are presented as median (interquartile range) or number (%).

INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LV, left ventricle; NYHA, New York Heart Association; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; hsCRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal-pro hormone B-type natriuretic peptide; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; RA, right atrium; PA, pulmonary artery; PWP, pulmonary wedge pressure; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; ACE, angiotensin-converting enzyme; ICD, implantable cardioverter-defibrillator; CRT, cardiac resynchronization therapy; BTT/BTC, bridge to transplantation/bridge to candidacy; DT, destination therapy; HVAD, HeartWare Ventricular Assist Device.